Amino-terminal protein-protein interaction motif (POZ-domain) is responsible for activities of the promyelocytic leukemia zinc finger retinoic acid receptor alpha fusion protein

被引:151
作者
Dong, S
Zhu, J
Reid, A
Strutt, P
Guidez, F
Zhong, HJ
Wang, ZY
Licht, J
Waxman, S
Chomienne, C
Chen, Z
Zelent, A
Chen, SJ
机构
[1] SHANGHAI MED UNIV 2,RUI JIN HOSP,SAMUEL WAXMAN CANC RES FDN LAB,SHANGHAI INST HEMATOL,SHANGHAI 200025,PEOPLES R CHINA
[2] INST CANC RES,CHESTER BEATTY LABS,LEUKAEMIA RES FUND CTR,LONDON SW3 6JB,ENGLAND
[3] HOP ST LOUIS,CTR HAYEM,BIOL CELLULAIRE HEMATOPOIET LAB,F-75010 PARIS,FRANCE
[4] MT SINAI MED CTR,DEPT MED,DIV MED ONCOL,ROCHELLE BELFER CHEMOTHERAPY FDN LAB,NEW YORK,NY 10029
关键词
D O I
10.1073/pnas.93.8.3624
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Promyelocytic leukemia zinc finger-retinoic acid receptor alpha (PLZF-RAR alpha), a fusion receptor generated as a result of a variant t(11;17) chromosomal translocation that occurs in a small subset of acute promyelocytic leukemia (APL) patients, has been shown to display a dominant-negative effect against the wild-type RAR alpha/retinoid X receptor alpha (RXR alpha). We now show that its N-terminal region (called the POZ-domain), which mediates protein-protein interaction as well as specific nuclear localization of the wild-type PLZF and chimeric PLZF-RAR alpha proteins, is primarily responsible for this activity, To further investigate the mechanisms of PLZF-RAR alpha action, we have also studied its ligand-receptor, protein-protein, and protein-DNA interaction properties and compared them with those of the promyelocytic leukemia gene (PML)-RAR alpha, which is expressed in the majority of APLs as a result of t(15;17) translocation, PLZF-RAR alpha and PML-RAR alpha have essentially the same ligand-binding affinities and can bind in vitro to retinoic acid response elements (RAREs) as homodimers or heterodimers with RXR alpha. PLZF-RAR alpha homodimerization and heterodimerization with RXR alpha were primarily mediated by the POZ-domain and RAR alpha sequence, respectively, Despite having identical RAR alpha sequences, PLZF-RAR alpha and PML-RAR alpha homodimers recognized with different affinities distinct RAREs. Furthermore, PLZF-RAR alpha could heterodimerize in vitro with the wild-type PLZF, suggesting that it may play a role in leukemogenesis by antagonizing actions of not only the retinoid receptors hut also the wild-type PLZF and possibly other POZ-domain-containing regulators. These different protein-protein interactions and the target gene specificities of PLZF-RAR alpha and PML-RAR alpha may underlie, at least in part, the apparent resistance of APL with t(11;17) to differentiation effects of all-trans-retinoic acid.
引用
收藏
页码:3624 / 3629
页数:6
相关论文
共 35 条
[21]   NUCLEAR RECEPTOR THAT IDENTIFIES A NOVEL RETINOIC ACID RESPONSE PATHWAY [J].
MANGELSDORF, DJ ;
ONG, ES ;
DYCK, JA ;
EVANS, RM .
NATURE, 1990, 345 (6272) :224-229
[22]   FUSION OF A KINASE GENE, ALK, TO A NUCLEOLAR PROTEIN GENE, NPM, IN NON-HODGKINS-LYMPHOMA [J].
MORRIS, SW ;
KIRSTEIN, MN ;
VALENTINE, MB ;
DITTMER, KG ;
SHAPIRO, DN ;
SALTMAN, DL ;
LOOK, AT .
SCIENCE, 1994, 263 (5151) :1281-1284
[23]  
NERVI C, 1992, CANCER RES, V52, P3687
[24]   PMLRAR HOMODIMERS - DISTINCT DNA-BINDING PROPERTIES AND HETEROMERIC INTERACTIONS WITH RXR [J].
PEREZ, A ;
KASTNER, P ;
SETHI, S ;
LUTZ, Y ;
REIBEL, C ;
CHAMBON, P .
EMBO JOURNAL, 1993, 12 (08) :3171-3182
[25]   CHROMOSOMAL TRANSLOCATIONS IN HUMAN CANCER [J].
RABBITTS, TH .
NATURE, 1994, 372 (6502) :143-149
[26]  
REDNERRL, 1994, BLOOD, V87, pA375
[27]   LEUKEMIA AND THE DISRUPTION OF NORMAL HEMATOPOIESIS [J].
SAWYERS, CL ;
DENNY, CT ;
WITTE, ON .
CELL, 1991, 64 (02) :337-350
[28]   SINGLE-STEP PURIFICATION OF POLYPEPTIDES EXPRESSED IN ESCHERICHIA-COLI AS FUSIONS WITH GLUTATHIONE S-TRANSFERASE [J].
SMITH, DB ;
JOHNSON, KS .
GENE, 1988, 67 (01) :31-40
[29]  
TONG JH, 1992, ONCOGENE, V7, P311
[30]   ACUTE PROMYELOCYTIC LEUKEMIA [J].
WARRELL, RP ;
DETHE, H ;
WANG, ZY ;
DEGOS, L .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (03) :177-189